Daniel Rechtman research award (DRRA)
The Daniel Rechtman Research Award was established to mark the 20th anniversary of the commencement of the CASS Medicine/Science grants in 2002 and to celebrate Daniel Rechtman’s role as the founding Chair of The CASS Foundation.
CASS supports short term, ‘proof of concept’ research in promising topic areas, which if validated, has the potential to attract longer-term funding and to contribute to better practice and delivery of services.
Note -
Awards for the DRRA are by invitation only. There is no open application round.
Eligible Organisations - 2022 to 2024
CASS restricts applications for the Daniel Rechtman Research Award.
From 2022 to 2024, for three years, the designated eligible organisation is The Peter Doherty Institute for Infection and Immunity, University of Melbourne (Doherty Institute).
Only Applicants employed by the Doherty Institute will be invited to apply.
Funds Available
Applications for grants up to $75,000 (excluding GST) will be considered for specific research and development projects.
Project Period
A project which anticipates completion within 12 months from commencement may be given preference.
2023
CASS congratulates Dr Sapna Devi as the successful recipient of the 2023 Daniel Rechtman Research Award.
Dr Devi is part of The Peter Doherty Institute for Infection and Immunity's Department of Microbiology and Immunology, and her research project - – Investigating the role of stress in anti-tumour immunity – will iseek to understand the role of stress signals in the control of immune responses. Dr Devi expects that the outcomes of this project will improve fundamental knowledge of neuron functions and neuroimmune pathways, and will also benefit knowledge that could improve current cancer therapies and potential therapeutics for other diseases.
2022
CASS is pleased to announce that the successful recipient of the 2022 Daniel Rechtman Research Award was Dr Susan Christo.
Dr Christo is part of the Department of Microbiology and Immunology, and her research project – Investigating the radioresistant properties of cancer-specific resident T cells – will investigate how some immune cells found in melanoma can evade radiation therapy during cancer treatment, which may lead to improved radiation therapy treatment.
Contact Information
Any queries about DRRA Grants should be directed to:
David Abraham AM
[email protected]
0418 335 642
